All In Biotech

Drug Trial Radar · NCT07146386

A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia

A Randomized, Double-blind, Controlled, Non-inferiority Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of H077 Sustained-release Tablets Versus Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 728 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

728

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Jan 2027

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Aug 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic hyperplasia.

Conditions

  • Benign Prostatic Hyperplasia
  • Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

Interventions

  • H077 sustained-release tabletDrug

    Subjects are administered one H077 sustained-release tablet (8 mg) orally once daily, along with one silodosin capsule (placebo) orally twice daily.

  • Silodosin capsules Control GroupDrug

    Subjects are administered one Silodosin capsule (4 mg) twice daily, along with one H077 sustained-release tablet placebo once daily, orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. changes in International Prostatism Symptom Score (IPSS) at 12 weeks from baselineTime frame: baseline to 12 weeks

Locations

66 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Second People's Hospital of Hefei

    Hefei, Anhui, China

  • Beijing Tongren Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Fujian Provincial People's Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Zhangzhou Affiliated Hospital of Fujian Medical University

    Zhangzhou, Fujian, China

  • The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital)

    Dongguan, Guangdong, China

  • The Second Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • First Affiliated Hospital of Hebei University of Traditional Chinese Medicine

    Shijiazhuang, Hebei, China

  • The People's Hospital of Anyang City

    Anyang, Henan, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China

  • The Third Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, China

  • Zhengzhou People's Hospital

    Zhengzhou, Henan, China

  • Zhoukou Central Hospital

    Zhoukou, Henan, China

  • The Sixth hospital of Wuhan

    Wuhan, Hubei, China

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Wuhan Hospital of Traditional Chinese And Western Medicine

    Wuhan, Hubei, China

  • Yichang Central People's Hospital

    Yichang, Hubei, China

  • Changsha Central Hospital

    Changsha, Hunan, China

  • The First Affiliated Hospital of Nanhua University

    Hengyang, Hunan, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Jiangsu Provincial Hospital of Traditional Chinese Medicine

    Nanjing, Jiangsu, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, China

  • Nanjing Jiangning Hospital

    Nanjing, Jiangsu, China

  • Wuxi People's Hospital affiliated to Nanjing Medical University

    Wuxi, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • Ganzhou People's Hospital

    Ganzhou, Jiangxi, China

  • Affiliated Hospital of Jiujiang University

    Jiujiang, Jiangxi, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shaanxi Provincial People's Hospital

    Xi'an, Shaanxi, China

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.